Genetic modification of human bone marrow mesenchymal stem cells (MSC) is highly valuable for their exploitation in basic science and therapeutic applications, for example in cancer. We present here a new, fast and easy-to-use method to enrich a functional population of lentiviral (LV)-transduced MSC expressing enhanced green fluorescent protein (eGFP). We replaced the eGFP gene by a fusion gene of puromycin acetyltransferase and eGFP. Upon LV gene transfer and puromycin selection, we quickly obtained a pure transduced MSC population, in which growth, differentiation capacity and migration preferences were not compromised. Furthermore, we are the first to report the migration velocity of MSC among which 30% were moving and velocity of about 15 mm h À1 was not altered by LV transduction. Manipulated MSC underwent senescence one passage earlier than non-transduced cells, suggesting the use for therapeutic intervention in early passage numbers. Upon tail vein application in nude mice, the majority of LV-transduced MSC could be detected in human orthotopic pancreatic tumor xenografts and to a minor extent in mouse liver, kidney and lung. Together, LV transduction of genes to MSC followed by puromycin selection is a powerful tool for basic research and improves the therapeutic prospects of MSC as vehicles in gene therapy.
Introduction
Human mesenchymal stem cells (MSC) derived from bone marrow (BM) comprise an adult population that may participate in the repair of tissue damage inflicted by natural expiry of cells, injury or disease.
1 MSC comprises 0.01-0.001% of the BM-nucleated cells and are obtained by expansion and selection of the plastic-adherent cell fraction, since a single definitive marker that characterizes these cells is unknown until now. 2 MSC are thought to contribute to the regeneration of mesenchymal tissues such as bone, cartilage, muscle, ligament, tendon, adipose tissue and stroma. They have been reported to have the ability, at least in vitro, to differentiate also into nonmesenchymal cell types, 3 and can self-renew by proliferation without differentiation and thereby maintain their stem-cell phenotype. 4, 5 MSC have attracted much attention for their potential therapeutic applications, 1 and are suggested as attractive target cells for ex vivo gene delivery into solid tumors although studies exploiting MSC in the context of cancer are limited. The ability of MSC to migrate to areas of injury and to tumors has encouraged investigation of MSC as therapeutic tools. For example, systemically administered MSC have been shown to improve recovery in animal models of stroke and myocardial infarction. 6, 7 MSC have also been used for targeted delivery of therapeutic gene products to the tumor microenvironment in animal models, [8] [9] [10] and the therapeutic use of MSC is being explored for various disease conditions. Recent advances in studying MSC biology have shown that this cell population exhibits some properties that suggest the feasibility of their use as a cellular vehicle: a relative simple isolation method, the ability to be cultured in vitro and to expand to quantities required for therapy, the ability for ex vivo transduction with viral vectors, plasticity, the potential to differentiate under exogenous stimuli, high metabolic activity, an efficient machinery to express therapeutic proteins and the ability to be delivered systemically or locally. 11 A highly efficient gene transfer method is needed to circumvent the need for selective enrichment and long-term culture of MSC that may contribute to senescence or compromise multipotency. 12 This justifies the use of lentiviral vectors (LV) for transducing MSC by virtue of their ability to transduce both dividing and non-dividing cells. Furthermore, LV might be less prone to transcriptional silencing than other retroviral vectors. 13, 14 LV integrate stably into the target cell genome, which guarantees that the transgene is transmitted to the progeny of a transduced cell in an expanding BM-derived mesenchymal population. Transduction with adenoviral vectors is generally less efficient and requires very high vector doses. 11 In contrast, LV transduction systems were shown to be highly efficient for stable genetic modification of human stem cells and they mediate the delivery of the entire DNA cassette. [15] [16] [17] Self-inactivating human immunodeficiency virus type 1 vectors, in which the proviral integrants are lacking enhancer-promoter activity within their LTRs, have a reduced risk of clonal dominance and procancerous effects, which were reported following transduction with murine leukemia retroviruses. 18, 19 In the present study, we compared two different marker genes and their use in purification of LV-transduced cells, and we investigated the properties of LV-transduced MSC. We have isolated human MSC from BM followed by ex vivo transduction with LV-transduced enhanced green fluorescent protein (eGFP) or an eGFP-puromycin acetyltransferase fusion gene. By fluorescence-activated cell sorting (FACS), the eGFP-expressing MSC population could be enriched to nearly 100%. We could circumvent the time-consuming and cell-stressing FACS sorting procedure by replacing the eGFP by an eGFPpuromycin acetyltransferase fusion gene and obtained similar purities by puromycin selection of transduced cells. Analysis of phenotype, growth, differentiation capacity, velocity and migration ensured that neither LV transduction nor puromycin selection compromised phenotype or multipotency. Moreover, in nude mice, LV-transduced MSC were easily detectable preferentially in human orthotopic pancreatic tumor xenografts by FACS analysis and immunofluorescence staining of GFP.
Materials and methods
Isolation and in vitro culture of human BM-derived MSC Human BM was isolated from healthy donors between 25 and 35 years after approval by the Heidelberg University Ethical board, as previously described. 20, 21 About 50 ml BM aspirate was obtained from the iliac crest and collected in a syringe containing 10 000 IU heparin to prevent coagulation. Due to the lack of a single definitive marker for MSC, these cells were purified by three criteria: (I) plastic adherence, (II) positive for expression of CD105, CD73, CD90, (III) lack of expression of hematopoietic antigens like CD45, CD34 and markers for monocytes, macrophages and B cells. We ensured by several control experiments that isolated MSC behave their CD34
À phenotype even after several rounds in culture. 20 In addition, we cultured the MSC in medium for hematological cells (RPMI, 10% fetal calf serum (FCS) or Stemline II medium, thrombospondin (TPO 80 ng ml
À1
), stem cell factor (SCF, 50 ng ml
), FL-3 ligand (50 ng ml À1 )) and did not find differentiation of the MSC to a CD34 þ phenotype. 22 In brief, the mononuclear cell fraction was isolated by Biocoll densitygradient centrifugation (d ¼ 1.077 g cm
À3
; Biochrom, Berlin, Germany). MSC were cultivated as described. 4 In brief, the medium consists of 58% Dulbecco's modified Eagle's medium-low glucose (DMEM-LG, Cambrex, Apen, Germany) and 40% MCDB201 (Sigma, Deisenhofen, Germany), 2% FCS (HyClone, Bonn, Germany), supplemented with 2 mM L-glutamine, 100 U ml À1 Pen/ Strep (Cambrex), 1% insulin, transferrin, selenium, 1% linoleic acid bovine serum albumin, 10 nM dexamethasone, 0.1 mM L-ascorbic-acid-2-phosphate (all from Sigma), platelet-derived growth factor-bb (PDGF-bb) and EGF (10 ng ml À1 each; R&D Systems, Wiesbaden, Germany). Tissue culture flasks were coated with 0.1% fibronectine (Sigma) in phosphate-buffered saline (PBS) before use.
Tumor cell lines and culture
The established pancreatic carcinoma cell lines MIA-PaCa-2 and Capan-1 were grown at 37 1C in Dulbecco's modified Eagle's medium. Dulbecco's modified Eagle's medium was supplemented with 10% heat-inactivated fetal bovine serum, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and 2 mM L-glutamine (all from PAA, Co¨lbe, Germany).
Lentivirus construction and production
Vectors used in our study are the self-inactivating vectors of the second generation, which lose the activity of the promoter located in the 5 0 -LTR upon replication and integration into the genome of the host cells. The pLL3.7puroeGFP vector plasmid was modified from the recently described pLL3.7, 23 a gift of Dr L Van Parijs, by in-frame cloning of the puromycin acetyltransferase gene from pBabe-Puro, 24 in front of the eGFP gene by standard cloning techniques. The details of clone construction will be provided upon request. The construct was verified by sequencing. LV production was performed as previously described. 25, 26 Transduction of MSC Cells were seeded in six-well plates at 2 Â 10 5 -2 Â 10 6 cells per well in 2-5 ml MSC medium containing 8 mg ml À1 polybrene and virus was added to the cells at different multiplicities of infection. The plates were centrifuged at 1200 r.p.m., 37 1C for 1 h and incubated at 37 1C. Medium was changed after 6-16 h. Infected MSC were sorted by flow cytometry and gating on eGFP-derived green fluorescence or selected by continuous incubation in MSC medium plus 10 mg ml À1 puromycin (Sigma) starting 1 day after transduction. Prior to experiments, MSC were cultured 48 h without puromycin.
Flow cytometry analysis of MSC Enhanced green fluorescent protein-expressing MSC were detected by flow cytometry analysis using a FACScan flow cytometer (Becton Dickinson, Heidelberg, Germany). Cells were gated according to their high fluorescence intensity.
Immunofluorescence of GFP in cell lines and tissue Mesenchymal stem cells were grown in cell culture dishes, fixed in 4% paraformaldehyde for 15 min and permeabilized in 0.2% Triton X-100 for 15 min. The cells were incubated with mouse anti-eGFP antibody 1:200 (JL8; BD Clontech, Heidelberg, Germany) in PBS/5% milk and detected with goat anti-mouse antibody Alexa-fluor 647 (Invitrogen, Karlsruhe, Germany) 1:300 in PBS/5% milk. Nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (Sigma) in PBS. Cryosections of normal mouse pancreas and human pancreatic cancer xenografts were 4 0 ,6-diamidino-2-phenylindole-stained. Blue and green fluorescence, derived from GFP-expressing MSC, were detected by immunofluorescence microscopy.
Evaluation of MSC differentiation
Adipogenesis. Cells were seeded at a concentration of 2.5 Â 10 4 cm À2 in a 24-well plate. The next day, adipogenic medium containing 10 ng ml À1 insulin (Sigma) and 1 Â 10 À8 M dexamethasone (Sigma) was added. The cells were grown for 1-3 weeks, with medium replacement twice a week. Adipogenesis was detected by oil red O staining.
Osteogenesis. Cells were seeded at a concentration of 2.5 Â 10 4 cm À2 in a 24-well plate. The next day, osteogenic medium containing 50 mg ml À1 L-ascorbic acid 2-phosphate, 10 mM glycerol 2-phosphate disodium salt and 1 Â 10 À8 M dexamethasone (all from Sigma) were added. The cells were grown for 3-4 weeks with medium replacement twice a week. Osteogenic differentiation was detected by von Kossa staining.
MTT assay. Mesenchymal stem cells were seeded at 5 Â 10 5 ml À1 in 96-well plates, 100 ml per well. After treatment, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay was performed as recently described. 27 Migration to chemoattractants measured by transwell chamber migration assay A ChemoTx System (Neuro Probe Inc., Gaithersburg, MD, USA) with 96 wells was used for the migration assay. The polycarbonate membrane pore size of 12 mm was selected to allow passage of mammalian cells. The bottom chamber contained platelet-derived growth factor (PDGF; R&D Systems) in medium with 2% FCS or cell culture supernatant of tumor cells grown in medium supplemented with 2% FCS for 2 days. A total of 6 Â 10 3 MSC were placed on the filter top. A calibration series with known MSC numbers in microplate wells below the filter was also performed. Migration assays were terminated after 72 h and migrated MSC were detected in an MTT assay according to the instructions of the manufacturer (www.neuroprobe.com/protocols/ info_auto.html).
Migration velocity measured by digital time-lapse microscopy Mesenchymal stem cell migration in collagen type I matrix was investigated using a MiniPOC chamber (Lacon GbR, Ulm, Germany). This temperature-controlled chamber has a depth of 0.7 mm, a diameter of 28 mm and a volume of approximately 400 ml. Collagen matrix was prepared according to the instructions of the manufacturer (Serva, Heidelberg, Germany). In brief, 2 Â 10 5 cells in 100 ml cell culture medium were added to a mixture containing 1.7 ml of collagen type I solution (Collagen R; Serva), 266 ml of 10 Â cell culture medium and 110 ml of 0.34 M NaOH. The gel was immediately filled into the chamber and polymerized for 30 min at 37 1C. MSC migration was recorded by digital time-lapse microscopy over 24 h. For this aim, one microscopic field containing at least 100 MSC was identified using a special microscope (Leica GmbH, Wetzlar, Germany) and an objective with fivefold magnification, transmitted by digital video camera (DX2H, Kappa GmbH; Gleichen, Germany) and saved on a computer in time-lapse manner as a line of consecutive images (1 image per 15 min, TIFformat, 8-bit) using Kappa Image Base 2.7.2 software (Kappa). These images were processed to video sequences using the Animation Shop 3.04 software (Corel co., Minneapolis, MN, USA), which exhibited the cell movement with optional acceleration. The migration of MSC was analyzed using special software (Capimage 8.02, Zeintl GmbH, Heidelberg, Germany). The migration velocity of 10 MSC expressing highest migratory activity was measured using 'frame-to-frame' method.
Orthotopic pancreatic cancer xenograft model in athymic nude mice Six-to ten-week-old NMRI (nu/nu) male mice were used for subcutaneous and orthotopic tumor implantations as described previously. 28 The experimental protocol was approved by the Chancellor's Animal Research Committee of the University of Heidelberg (Heidelberg, Germany) in accordance with national guidelines for animal care and the use of laboratory animals. The poorly differentiated human pancreatic cancer cell line MIA-PaCa-2 was used for xenograft tumor induction. After subcutaneous tumor formation, one small tumor fragment (2-3 mm in diameter) was removed from the subcutaneous tumor and transplanted into the tail of the mouse pancreas of 10 mice. After orthotopic tumor transplantation, the mice were inspected daily. The growth rate of the tumor was monitored by abdominal palpation. After 3-4 weeks of tumor development, mice received transduced or non-transduced MSC at 6 Â 10 5 per 200 ml PBS into the tail vein. Three days later, mice were euthanized following principles of animal protection. Xenografts and organs were resected and digested over night in collagen type 1A collagenase from Clostridium HI (C9891; Sigma). Cells were diluted in RPMI supplemented with 20% heat-inactivated fetal bovine serum (Sigma), 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 2 mM L-glutamine and Pen/Strep (all from PAA), counted by trypan blue exclusion followed by immediate analysis of eGFP expression by flow cytometry.
Results

Puromycin selection of LV-transduced MSC is superior to FACS sorting
Human MSC were isolated and cultured according to a protocol described elsewhere. 20, 21 After two passages in vitro they represented a mainly homogeneous population of fibroblast-shaped cells as assessed by cell morphology (compare Figures 1c and 2 ). To determine whether BM-derived MSC could be transduced efficiently with lentiviral vectors, a subconfluent MSC culture was infected with VSV-G-pseudotyped HIV SIN -CMV-eGFP vector particles (Figure 1a) . Three days later, eGFP-positive cells were analyzed by flow cytometry and eGFP expression rates of 23, 46 and 80% accordant to the respective multiplicities of infection of 2, 5 and 10 were found (Figure 1b) . However, transduction efficiency was variable and depended on the donor and quality of MSC (data not shown). To further enrich the eGFPexpressing MSC, we used FACS sorting and gating on green fluorescent cells. This resulted in a 98% enriched eGFP-expressing MSC population (Figure 1c, day 1) . However, 7 days after sorting, only 50% of MSC still expressed the marker gene ( Figure 1, day 7) . This indicates that the low percentage of non-transduced MSC has a survival advantage and overgrows the transduced MSC and, together with FACS sorting, may lead to a slower growth of transduced cells (data not shown).
To improve the purity of transduced cell populations and to circumvent FACS sorting, we modified the pLL3.7puroeGFP vector plasmid by in-frame cloning of the puromycin acetyltransferase gene from pBabe-Puro upstream of the eGFP gene ( Figure 2 ). This fusion gene can be used as a marker for both flow cytometry and drug selection, since the puromycin acetyltransferase confers puromycin resistance. To test the functionality of this alternative enrichment method, MSC were transduced with pLL3.7puroeGFP and were selected in the presence of 1, 5 or 10 mg ml À1 puromycin. Non-transduced MSC started to die 24 h after puromycin and the percentage of death increased corresponding to rising amounts of puromycin (data not shown). Selection was completed 72 h after incubation with 10 mg ml À1 puromycin and resulted in a 100% eGFP-expressing population as detected by fluorescence microscopy. Therefore, we used in all following experiments, 10 mg ml À1 puromycin for enrichment of LV-transduced MSC.
Characterization of LV-transduced and puromycin-selected MSC The growth of LV-transduced, puromycin-selected and non-transduced MSC was detected at passage 4 by staining of cell colonies by Coomassie blue (Figure 3a) . The number of viable cells varied with no noticeable significant changes in propagating characteristics. Likewise, mitochondrial activity referred to as viability was comparable between both cultures at passage 5 as measured by MTT assay (Figure 3b) . However, at higher passages, LV transduction resulted in faster senescence of MSC, as obvious from morphology and cell count ( Figure 3c ). While non-transduced MSC started to become senescent at passage 7, dependent on the donor, LV-transduced MSC from the same donor started to become senescent at passage 6.
To determine whether LV transduction together with puromycin selection might have altered the differentiation potential of MSC, cells were assayed for adipogenesis and osteogenesis under in vitro conditions (Figure 4a ) according to published procedures. 20 Adipogenic differentiation characterized by positive staining with oil red O for fat droplets in cells of the adipocyte lineage (Figure 4b ) and von Kossa-positive staining for cells of the osteogenic lineage ( Figure 4c) were observed under appropriate conditions for both LV-transduced and non-transduced MSC. Furthermore, eGFP-expressing adipocytes could be generated from LV-transduced MSC as detected by immunofluorescence staining (Figure 4b, lower panel) . eGFP expression in LV-transduced osteoblasts could not be documented by fluorescence microscopy, since the thick layer of secreted bone fibers covered the green fluorescent cells below.
To detect whether LV transduction might have altered migration capacity, MSC were seeded in a collagen type I matrix in a temperature-controlled chamber and migration velocity was recorded by digital time-lapse microscopy over 24 h (Figure 5a ). No significant difference in migration velocity was detected, since LV-transduced MSC moved with 16.7 mm h À1 and nontransduced MSC with 15.1 mm h À1 with 30% traveling cells in both fractions. Next, MSC have been described to migrate in transwell assays to conditioned medium of prostate, colorectal and breast cancer cells 29 and toward growth factors like PDGF. 30, 31 To investigate the in vitro migration preferences of LV-transduced MSC, we used the pancreatic cancer cell lines MIA-PaCa-2 and Capan-1 as well as PDGF as chemoattractants in a transwell migration assay (Figure 5b ). Three days after incubation, the highest and significant chemotactic activity of MSC was observed toward MIA-PaCa-2 cells, followed by Capan-1 and PDGF, with no obvious and significant difference between migration preferences of transduced and non-transduced MSC populations.
In vivo migration and detection of LV-transduced MSC
Mice with a human orthotopic pancreatic cancer xenograft were injected with LV-transduced MSC (6 Â 10 5 in tail vein). Mice that did not receive MSC served as controls. Three days later, mice were killed followed by resection of xenografts and organs. Isolated cells were examined by flow cytometry for eGFP expression, which is shown as percentage of tumors and organs of mice that received no MSC (Figure 6a ). The highest GFP expression was observed in xenograft cells, but a minor percentage was also detected in normal mouse organs such as liver, lung and kidney. This result indicates a tumor-specific migration of MSC but shows also that some MSC reside in other organs according to a natural function of MSC in tissue remodeling. 5 We also examined cryosections of normal mouse pancreas and human pancreatic cancer xenografts (Figure 6b) . In this case, we detected green fluorescence only in the cancerous but not in the normal pancreas. This result indicates that 5 MSC in 100 ml medium were added to a mixture containing collagen type I solution, 10 Â medium and NaOH. The gel was immediately filled into a temperature-controlled chamber and MSC migration was recorded by digital time-lapse microscopy over 24 h. For this, one microscopic field containing at least 100 MSC was identified by microscopy and fivefold magnification, transmitted by digital video camera and saved on a computer in time-lapse manner as a line of consecutive images. These images were processed to video sequences that exhibited the cell movement with optional acceleration. The migration of MSC was analyzed using special software and the number of all migrating cells was measured and found to be 30% of total cell number. The migration velocity of 10 MSC expressing highest migratory activity was measured using 'frame-to-frame' method. In this way, we determined a migration velocity of 15.1±4.1 mm h À1 for non-transduced MSC (ÀLV) and of 16.7 mm h À1 ±6.7 for transduced MSC ( þ LV). (b) In vitro migration of non-transduced (ÀLV, white bars) and transduced MSC ( þ LV, black bars) toward platelet-derived growth factor (PDGF) (200 ng ml À1 in medium containing 2% FCS) or conditioned medium of the pancreatic cancer cell lines MIA-PaCa-2 or Capan-1, which have been cultured in medium containing 2% FCS for 48 h. Migration was measured in a ChemoTx system as described in Materials and methods. After incubation for 3 days, migrated MSC that remained in the lower face of the filters were counted by trypan blue exclusion. Results presented are from three independent experiments for each condition. LV, lentiviral vector; MSC, mesenchymal stem cells.
MSC within one organ may home preferentially to the tumor cells.
Discussion
Recent evidence suggests that MSC selectively home to tumors, where they contribute to the formation of tumorassociated stroma. 32 MSC might even contribute to tumor angiogenesis, although this latter point is critically discussed. 33, 34 While the molecular processes that drive migration of MSC to tumor tissues remain unclear, the tropism of MSC to tumor tissues is suggested to be mediated, at least in part, by specific growth factors and chemokines, 30, 31 such as also shown in the present study on PDGF. Consequently, to inhibit the growth of tumors in situ by MSC, genetic modification of MSC is necessary to produce high levels of anticancer agents that blunt tumor growth kinetics. In addition to the tumor-specific targeting by MSC, such cell vehicles may have another advantage compared to uncovered administration of viral vectors. Thus, application of MSC has no apparent adverse side effects, since the mice in our experiments looked healthy after administration of MSC, and another report demonstrated that MSC overexpressing the adenoviral-transduced NK4 gene did not lead to enhanced liver enzymes in serum. 35 Therefore, selective engraftment of MSC expressing an antitumor agent in the tumor tissues should be sufficiently therapeutically advantageous to warrant further clinical trials. However, practical realization of efficient gene transfer by MSC vehicles has been limited. Previously, it has been shown that MSC could be transduced with an LV HIV SIN -CMV-GFP vector. 36 Transduction resulted in nearly 100% of the cells expressing GFP after successive transduction rounds. This vector was also used in our study and includes the reporter gene eGFP under the regulation of the cytomegalovirus (CMV) promoter, 15, 16 the human immunodeficiency virus type 1 central polypurine tract (cPPT) and woodchuck hepatitis regulatory element (WPRE) 16, 17 to improve proviral integration and expression in human stem cells. Nevertheless, the utilization of this LV was associated with significant limitations. As observed by the authors, 36 and in our first experiments, the expression levels in non-selected polyclonal transduced human MSC have been variable. This may be related to the number of integrated vectors per cell, chromosomal position effects and other factors. The variability may be alleviated by clonal expansion of transduced MSC, but cloning of human stem cells is inefficient and labor intensive. 37 To circumvent this problem, we enriched in a first attempt, transduced and GFP-expressing MSC by FACS sorting. However, the percentage of cells expressing the transgene after sorting declined with time, as described also by other researchers. 13, 36, 38 Finally, FACS sorting was stressful for the MSC since LV-transduced and FACS-sorted MSC grew much slower than parental cells.
We therefore optimized gene transfer by LV infection of MSC to establish an efficient, quick and easy use of these manipulated progenitors as gene transfer vehicles in tumor therapy. We used the self-inactivating LV vector pLL3.7-eGFP, 23 which is similar to the described LV vector above and contains a CMV promoter, as well as cPPT and WPRE elements. To select transduced cells, we replaced the eGFP gene of the lentiviral vector by a fusion gene of puromycin acetyltransferase and eGFP. To rule out that LV transduction and puromycin selection might have altered growth, migration, velocity and differentiation characteristics of MSC, making them useless for gene therapy studies, we examined the characteristics of these progenitor cells in detail. The differentiation potential of MSC was not affected by LV transduction and puromycin selection, since MSC were able to differentiate to osteocytes and adipocytes. These data are confirmed by recent results of van Damme and colleagues, 36 which achieved a 99.9% expression of eGFP in MSC by using several transduction rounds without puromycin or FACS selection. However, this enrichment method is much more time consuming and expensive than simple puromycin selection. Van Damme reported that after 4 months of continuous in vitro culture, eGFP expression was still detectable in 98% of the transduced cells. This finding of a 4-month culture period of MSC is different from our results since we were not able to culture MSC for such a long period of time in vitro. Dependent on the donor, we observed a senescent phenotype starting between passages 7 and 12 accordant to the observation of Kern et al., 39 who found a senescent phenotype characterized by an altered morphology resembling senescent cells and ceased proliferation within 3-5 weeks after subcultivation of MSC. While in earlier passages, growth characteristics, mitochondrial activity, migration preferences and migration velocity did not differ significantly between LVtransduced and non-transduced MSC in our cultures, we detected decline of growth in LV-transduced MSC one passage earlier than in non-transduced MSC. The lower proliferation rate was associated with the onset of senescence, characterized by telomere shortening as described in previous studies using MSC. 40 This senescence might have led to reduced proliferation in culture, which was previously shown to diminish transgene (eGFP) expression in other cell populations containing adult stem cells, such as neural stem cells. 41 These results suggest that the transgene, in our case the eGFP marker gene, rather than the LV vector itself, induced earlier senescence of MSC. It is known that eGFP can be toxic to certain cells, resulting in the inability of stable cell clones to express the protein 42 or in phenotypic changes in neuronal progenitor cells. 43 In this context, van Damme et al. 36 also observed a slightly impaired differentiation of MSC to osteocytes in their system and concluded that this may represent a more subtle effect of GFP toxicity. We did not observe an impaired differentiation potential when we used the MSC in passages 3-6. However, it is thinkable that at higher passages, the transduced MSC may start slowly losing their differentiation potential. Another reason for the discrepancy may be that the fusion of eGFP with puromycin acetyltransferase in our vector may have reduced toxicity since several transduction rounds used in the other paper is a stressful procedure for the cells and is therefore avoided in our approach.
We also showed that efficient engraftment of LVtransduced MSC could be obtained in vivo. To achieve this, MSC transduced with the LV-eGFP vector were injected into the tail vein of nude mice transplanted with human orthotopic pancreatic xenografts. Efficient engraftment of the engineered cells mainly in the tumor and to minor extends in liver, kidney and lung was apparent by eGFP fluorescence detected in the isolated tissues. Besides homing to tumors it has been demonstrated that MSC tend to home to sites of injury or damaged tissue irrespective of the tissue type. This ability of MSC has been verified in experiments with brain injuries, 7 wound healing and tissue regeneration sites. 44 This raises the question whether migration of MSC is induced by regenerative tissue remodeling by wound healing of the implantation side. However, there is evidence against migration of MSC to the wound we made by xenografting in our orthotopic model. This is related to the operation technique, the time point of MSC injection and the fact that we did not find MSC in normal pancreatic tissue near the implantation side. First, the orthotopic tumor model used by us is not associated with severe tissue damage since only a small tissue pocket is generated using a microscissor and blunt parenchymal dissection. In this pocket, a very small tumor fragment from a subcutaneous tumor is inserted without any need to further anchor the tumor transplant since the tissue texture will cause spontaneous closure of the pocket. It is also noteworthy that there is virtually no bleeding in the implantations procedure. Second, MSC were injected after a period of 4 weeks of tumor growth. At this time point, there should be no active wound healing due to the implantation process. Tissue remodeling might be due to ongoing rapid tumor expansion in the pancreas rather than due to the primary tumor inocculation. This is also of importance since in this study, MSC require a functional vascular network that is triggered by the tumor. Nevertheless, ongoing tumor growth certainly leads to local tissue remodeling and adaptive processes including neoangiogenesis, lymphovascular development and establishment of the specific tumor stroma, which may be involved in homing of MSC. Finally, our finding that MSC did not home to normal pancreatic tissue close to a putative wound, but specifically to the tumor xenograft speaks against the theory of homing to wound/tissue remodeling based on the initial implantation surgery. Our finding is consistent with another report that demonstrates preferential homing of systemically administered MSC to xenografted malignant cells. MSC, which became incorporated into the tumor architecture, could selectively proliferate and served as precursors for stromal tumor fibroblasts. 8 The authors of this report related tumor homing of MSC to high local concentrations of paracrine growth factors and other mediators within the tumor microenvironment. 9 Apparently, signals for the site of damage are required for MSC to travel and fill this niche by engrafting and proliferating. Fibroblasts have demonstrated a similar effect of accumulating at the site of injury. 45 Theoretically, a tumor can be considered as a 'never healing wound' or at least as a site of production of cytokines and chemokines. We confirmed the in vitro homing capacity of MSC, which showed a strong affinity for pancreatic cancer cells or PDGF. Besides, we were the first to measure the migration velocity of MSC and found that 30% of MSC are moving with approximately the same velocity as most active tumor cells of pancreatic carcinoma lines (unpublished data).
The efficiency of LV vectors for MSC transduction facilitates possible scaling-up for gene transfer studies in large animal models or ultimately for clinical trials. However, a possible disadvantage of efficient lentiviral transduction is the higher risk for insertional oncogenesis following multiple vector integrations. [46] [47] [48] [49] This risk may be diminished in our system, since we transduced the MSC only once followed by puromycin selection, in contrast to other groups that used several rounds of infection to achieve efficient transduction. 36 Nevertheless, the use of self-inactivating vectors potentially diminishes the risk of activating neighboring proto-oncogenes. LV gene transfer compares favorably with other gene transfer methods for introducing genes into MSC. In particular, transduction of MSC with adenoviral vectors seems relatively inefficient compared with LV gene transfer, which is at least partly a result of the limited expression of the cellular coxsackie and adenovirus receptor on the MSC. 11, 50 In addition, unlike LV vectors, adenoviral vectors do not integrate in a typically dividing MSC cell population. Consequently, the potentially therapeutic transgene is diluted over time, limiting the use of adenoviral vectors to gene therapy of disorders that would benefit only from short-term expression of a potentially therapeutic transgene in MSC.
Taken together, the current study presents a new, effective, quick and easy-to-perform method for enrichment of functional LV-transduced MSC. The potential of MSC as cell-based vectors for delivery of therapeutic genes certainly warrants further investigation. Our observations to date establish some of the key properties of LV transduction of MSC that allow them to function as cellular vectors and thus represent a rational strategy for cancer gene therapy.
